CRNX
Crinetics Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$84.95
+0.00%Year over year
Reported trailing growth
- Revenue
- +2928.4%
- EBITDA
- -30.0%
- EBIT
- -29.8%
- EPS
- -22.9%
- Free cash flow
- -39.1%
- Operating cash flow
- -40.9%
Forward estimates
Based on analyst estimates
- Revenue
- +181.0%
- EBITDA
- +12.6%
- EPS
- +14.2%
Three-year CAGR
- Revenue
- +17.6%
- EBITDA
- -56.0%
- EBIT
- -52.5%
- Net income
- -55.9%
- EPS
- -34.1%
- Free cash flow
- -67.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026